Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
November 01 2021 - 4:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
promotion of Brendan Teehan to Executive Vice President, Chief
Operating Officer, Head of Commercial, effective immediately. Mr.
Teehan, previously Senior Vice President, Chief Insights and
Analytics Officer, will continue to report to Steve Davis, Chief
Executive Officer and continue to serve as a member of the
company’s Executive Management Committee. He will assume
responsibility for all sales and marketing functions, in addition
to his current responsibilities leading commercial strategy,
operations, patient services, and market access and
reimbursement.
“Brendan has been instrumental in executing our long-term growth
strategies and his proven capabilities in building and leading
commercial teams with a patient-centric approach make him an ideal
leader for Acadia’s next phase of growth and development,” said
Steve Davis, Chief Executive Officer.
Since joining Acadia, Mr. Teehan has built the company’s
insights, analytics and operations department, and has led the
company’s annual brand and business planning processes.
Operationally, he oversees Acadia’s principal decision making
bodies that set the company’s strategic priorities across the
commercial, clinical, operations and business development
functions.
Brendan Teehan joined Acadia in July 2018 and has more than 25
years of global experience in the healthcare industry. He has held
roles of increasing responsibility at biopharmaceutical companies,
including Johnson & Johnson and Amgen, and over the course of
his career he has led field sales, operations and marketing teams
in the U.S. and Europe and successfully launched small and large
molecule products. Mr. Teehan began his career with Johnson &
Johnson, where he held a variety of commercial roles across
numerous therapeutic categories including oncology, immunology,
inflammation, transplantation, chronic obstructive pulmonary
disease and asthma. Mr. Teehan joined Acadia from TESARO, Inc.,
where he served as vice president, building and leading the
company’s first provider support function designed to help
oncologists optimize patient care.
Mr. Teehan received his MBA from Carnegie Mellon University,
Tepper School of Business and his Bachelor of Arts degree in
Government and International Relations from the University of Notre
Dame.
Charmaine Lykins, Senior Vice President, Global Product Planning
and Chief Marketing Officer, and Amanda Morgan, Senior Vice
President, Chief Revenue and Customer Officer, will be leaving the
organization to pursue new opportunities after a brief transition
period.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on dementia-related psychosis, negative symptoms of
schizophrenia and Rett syndrome, and in early-stage clinical
research we are exploring novel approaches to pain management, and
cognition and neuropsychiatric symptoms in central nervous system
disorders. For more information, visit us at www.acadia-pharm.com
and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211101005861/en/
Media Contact: Acadia Pharmaceuticals Inc. Stephanie Fagan (858)
212-0534 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024